<DOC>
	<DOCNO>NCT01134042</DOCNO>
	<brief_summary>The purpose study compare efficacy safety fluticasone furoate/vilanterol ( GW642444 ) inhalation powder administer daily even fluticasone furoate inhalation powder administer alone daily even adolescent adult subject 12 year age old persistent bronchial asthma 24-week period .</brief_summary>
	<brief_title>Study HZA106829 : Efficacy/Safety Study Fluticasone Furoate/Vilanterol ( GW642444 ) Adult Adolescent Asthmatics</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Outpatient least 12 year age Both gender ; female childbearing potential must willing use birth control method Prebronchodilator FEV1 4090 % predict Reversibility FEV1 least 12 % 200mls Current asthma therapy include inhaled corticosteroid least 12 week prior first visit History lifethreatening asthma Respiratory infection oral candidiasis Asthma exacerbation within 12 week Concurrent respiratory disease disease would confound study participation affect subject safety Allergies study drug , study drug ' excipients , medication relate study drug Taking another investigational medication medication prohibit use study</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Fluticasone propionate</keyword>
	<keyword>asthma</keyword>
	<keyword>vilanterol</keyword>
	<keyword>GW642444</keyword>
	<keyword>Fluticasone furoate</keyword>
</DOC>